Kristin Burnette
Family · Knoxville, TNNPI 1013331677
Payments from drug & device makers
Across 180 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$412
- AstraZeneca$404
- Pfizer$324
- GSK$286
- E.r. Squibb & Sons, L.L.C.$200
- Bayer$168
- plus $1K from 29 others
What the payments were for
- Food & beverage$3,18897%
- Education$883%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 21 | $412 |
| AstraZeneca | 23 | $404 |
| Pfizer | 16 | $324 |
| GSK | 17 | $286 |
| E.r. Squibb & Sons, L.L.C. | 12 | $200 |
| Bayer | 10 | $168 |
| Amarin Pharma, Inc. | 9 | $150 |
| Amgen | 5 | $137 |
| Sumitomo Pharma America, Inc. | 6 | $127 |
| Lilly USA, LLC | 7 | $118 |
| Novartis | 5 | $91 |
| Johnson & Johnson | 5 | $84 |
| AbbVie | 5 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $68 |
| Abbott | 3 | $52 |
| Esperion Therapeutics, Inc. | 3 | $49 |
| Sanofi Pasteur Inc. | 3 | $48 |
| Daiichi Sankyo Inc. | 2 | $45 |
| Dexcom, Inc. | 2 | $42 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $40 |
| Phathom Pharmaceuticals, Inc. | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $35 |
| Edwards Lifesciences | 1 | $35 |
| Almatica Pharma LLC | 2 | $34 |
| Boehringer Ingelheim | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Impel Pharmaceuticals Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Inogen, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Eisai Inc. | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Merck | 1 | $12 |
How this compares
$3,276 in reported general payments places this provider in the 85th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 86 | $105,466 |
| OzempicSemaglutide | 49 | $66,152 |
| JanuviaSitagliptin Phosphate | 39 | $54,427 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $51,999 |
| XareltoRivaroxaban | 26 | $34,831 |
| FarxigaDapagliflozin Propanediol | 26 | $32,290 |
| JardianceEmpagliflozin | 18 | $30,249 |
| MounjaroTirzepatide | 18 | $27,783 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $23,192 |
| MyrbetriqMirabegron | 12 | $16,921 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $11,416 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $9,655 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $8,361 |
| Novolog FlexpenInsulin Aspart | 15 | $6,837 |
| OxycontinOxycodone Hcl | 12 | $5,432 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $324 | $105,46686 claims |
| Novo NordiskOzempic | $412 | $66,15249 claims |
| MerckJanuvia | $12 | $54,42739 claims |
| GSKTrelegy Ellipta | $286 | $51,99953 claims |
| Johnson & JohnsonXarelto | $84 | $34,83126 claims |
| AstraZenecaFarxiga | $404 | $32,29026 claims |
| Boehringer IngelheimJardiance | $30 | $30,24918 claims |
| Lilly USA, LLCMounjaro | $118 | $27,78318 claims |
| Astellas Pharma US IncMyrbetriq | $19 | $16,92112 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $127 | $3,65912 claims |
| AbbVieSynthroid | $76 | $2,45947 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,706 family providers in Tennessee.
Other family in Knoxville
- Dana WebberKnoxville$499K
- Tiffany SipeKnoxville$87K
- Ashley BonnellKnoxville$49K
- Stacey MaltmanKnoxville$34K
- Katherine JohnsonKnoxville$32K
- Ashley BellKnoxville$22K
- Carol HawkinsKnoxville$22K
- Mina FarrarKnoxville$21K
- Amy AllenKnoxville$21K
- Sarah HarderKnoxville$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.